Company: RVRC
Filing Date: 2025-10-03
Form Type: S-1/A
Source: 0001213900-25-096094
Chunk: 116

Company: Revium Rx.
Filing Date: 2025-10-03
Form: S-1/A
Chunk 116
---
 in which case they
shall be owned jointly by Yissum and LipoVation). LipoVation m has the right to grant sub-licenses to third parties in accordance with
the terms set forth in the Yissum Agreements.

<div align='center'>74</div>

Notwithstanding granting LipoVation the exclusive
license, Yissum and the Hebrew University of Jerusalem retained the right to make non-commercial, academic use of the technology at the
Hebrew University, including academic research sponsored by third parties that does not conflict or interfere with the license. In addition,
Yissum may grant licenses to third party academic or research institutions for non-commercial, academic research and teaching purposes
provided that any results from such efforts shall be the sole property of Yissum and shall be exclusively licensed to LipoVation under
the agreement. If Yissum desires to license or divest any of the intellectual property rights, the Company has the right of first negotiation
with respect to such rights. Under the license agreement, we are responsible for, and are required to exert, reasonable commercial efforts
to carry out the development, regulatory, manufacturing and marketing work necessary to develop and commercialize products under the agreement
in accordance with a specified development plan.

We paid Yissum a $35,000 license fee, and on each
anniversary date of the agreement we owe pay Yissum an annual license maintenance fee of $35,000. The license fee is credited against
royalties due to Yissum, and if we paid Yissum $100,000 during the previous year for research activities the license fee for said year
is not due. Pursuant to the terms of the license agreement, we owe Yissum $150,000 upon the first patient being enrolled in a Phase I
clinical trial; $300,000 upon the first patient in a Phase II clinical trial; $450,000 upon the first patient being enrolled in a Phase
III clinical trial; and $600,000 upon the earlier of the first commercial sale in either Europe or the U.S.

Royalties will be payable to Yissum at the rate
of 3% of sales of any products which use, exploit or incorporate technology covered by the Licensed Patents (“Net Sales”).

We also have to pay Yissum 13% of any proceeds
we receive from sublicensees other than royalties from a sublicensee.

The exclusive license agreements are in effect,
if not earlier terminated pursuant to the